NAGIOS: RODERIC FUNCIONANDO

Difficulties on the acces to innovative targeted therapies for lung cancer in Spain

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Difficulties on the acces to innovative targeted therapies for lung cancer in Spain

dc.contributor.author	Calvo, Virginia
dc.contributor.author	Camps Herrero, Carlos
dc.contributor.author	Carcereny, Enric
dc.contributor.author	Cobo, Manuel
dc.contributor.author	Dómine, Manuel
dc.contributor.author	Garcia Campelo, Rosario
dc.contributor.author	González Larriba, Jose Luís
dc.contributor.author	Guirado, Maria
dc.contributor.author	Hernando Trancho, Florentino
dc.contributor.author	Massuti Sureda, Bartomeu
dc.contributor.author	Nadal, Ernest
dc.contributor.author	Rodriguez-Abreu, Delvys
dc.contributor.author	Sánchez, Alfredo
dc.contributor.author	Sullivan, Ivana
dc.contributor.author	Provencio Pulla, Mariano
dc.date.accessioned	2023-09-05T14:52:19Z
dc.date.available	2023-09-05T14:52:19Z
dc.date.issued	2023
dc.identifier.citation	Calvo, Virginia Camps Herrero, Carlos Carcereny, Enric Cobo, Manuel Dómine, Manuel Garcia Campelo, Rosario González Larriba, Jose Luís Guirado, Maria Hernando Trancho, Florentino Massuti Sureda, Bartomeu Nadal, Ernest Rodriguez-Abreu, Delvys Sánchez, Alfredo Sullivan, Ivana Provencio Pulla, Mariano 2023 Difficulties on the acces to innovative targeted therapies for lung cancer in Spain Clinical & Translational Oncology
dc.identifier.uri	https://hdl.handle.net/10550/89077
dc.description.abstract	Purpose Spanish Lung Cancer Group (SLCG) conducted a review to analyze the barriers to access to innovative targeted therapies for non-small cell lung cancer (NSCLC) in clinical practice in Spain. Methods Review all relevant content published on websites of European Commission, European Medicines Agency, and Spanish Agency of Medicines and Medical Products regarding the authorization and access to oncology treatments. Results More than 20 targeted therapies are available to treat different molecular alterations in patients with NSCLC. European Commission has approved treatments for genomic alterations involving the following genes: ALK, RET, ROS1, EGFR, BRAF, NTRK, KRAS, MET. However, the availability of these therapies in Spain is not complete, as innovative treatments are not reimbursed or funded late, with only five of these alterations currently covered by National Health System. Conclusion SLCG considers imperative to improve the access in Spain to innovative treatments for NSCLC to reduce inequity across European countries.
dc.language.iso	eng
dc.relation.ispartof	Clinical & Translational Oncology, 2023
dc.subject	Càncer
dc.subject	Medicina Pràctica professional
dc.subject	Pulmons Malalties
dc.title	Difficulties on the acces to innovative targeted therapies for lung cancer in Spain
dc.type	journal article
dc.date.updated	2023-09-05T14:52:19Z
dc.identifier.doi	10.1007/s12094-023-03303-5
dc.identifier.idgrec	161071
dc.rights.accessRights	open access